Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients
Eloxx Pharmaceuticals, a leader in ribosomal RNA-targeted genetic therapies for rare diseases, have announced the […]
Vertex Announces FDA Approval for TRIKAFTA in Children With Cystic Fibrosis
Vertex Pharmaceuticals has announced the U.S. Food and Drug Administration (FDA) approved the expanded use […]
Cystic Fibrosis Foundation Commits Up to $15.5M in Additional Funding for Potential Enzyme Therapy
The Cystic Fibrosis Foundation recently agreed to provide up to $15.5 million to Anagram Therapeutics […]
Gensaic Receives Funding From the CF Foundation to Develop a Gene Therapy for People With Cystic Fibrosis
Gensaic, a company that seeks to reimagine gene therapy, has announced that it has received […]
Armata Pharmaceuticals Announces Completion of its Phase 1b/2a 'SWARM-P.a.' Study of Inhaled AP-PA02 in Cystic Fibrosis Subjects
Armata Pharmaceuticals, a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more